A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and90yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma

Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients

(2012) Stephen M. Ansell et al.   AMERICAN JOURNAL OF HEMATOLOGY

Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation

(2012) M. Gupta et al.   BLOOD

A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer

(2012) N Steele et al.   BRITISH JOURNAL OF CANCER

Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: A clinic-based case-control study

(2012) Bridget Charbonneau et al.   CYTOKINE

Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus131Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016

(2012) Oliver W. Press et al.   JOURNAL OF CLINICAL ONCOLOGY

90Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial

(2012) Christian W. Scholz et al.   JOURNAL OF CLINICAL ONCOLOGY

Matched-Cohort Analysis of Autologous Hematopoietic Cell Transplantation with Radioimmunotherapy versus Total Body Irradiation–Based Conditioning for Poor-Risk Diffuse Large Cell Lymphoma

(2011) Amrita Krishnan et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report

(2011) Thomas E. Witzig et al.   LEUKEMIA & LYMPHOMA

Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia

(2011) Clive S. Zent et al.   LEUKEMIA & LYMPHOMA

New B-cell CD molecules

(2010) Jessica Matesanz-Isabel et al.   IMMUNOLOGY LETTERS

In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study

(2010) Joshua D. Brody et al.   JOURNAL OF CLINICAL ONCOLOGY

The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y]Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial

(2009) A. M. Evens et al.   CLINICAL CANCER RESEARCH

Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

(2009) Jane N. Winter et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma

(2008) Franck Morschhauser et al.   JOURNAL OF CLINICAL ONCOLOGY

Myeloablative 131I-Tositumomab Radioimmunotherapy in Treating Non-Hodgkin's Lymphoma: Comparison of Dosimetry Based on Whole-Body Retention and Dose to Critical Organ Receiving the Highest Dose

(2008) J. G. Rajendran et al.   JOURNAL OF NUCLEAR MEDICINE

Phase II Trial of a Transplantation Regimen of Yttrium-90 Ibritumomab Tiuxetan and High-Dose Chemotherapy in Patients With Non-Hodgkin's Lymphoma

(2007) Amrita Krishnan et al.   JOURNAL OF CLINICAL ONCOLOGY